Servier to Acquire KER-0193 from Kaerus Bioscience for ~$450M

Shots: Servier has entered into a definitive agreement with Kaerus Bioscience to acquire KER-0193, a potential treatment for Fragile X syndrome (FXS) As per the deal, Kaerus will receive a total of ~$450M incl. an upfront payment as well as development & commercial milestones KER-0193 is a BK channel modulator, which showed improvement across syndrome-relevant…

ByRidhi RastogiSeptember 8, 2025

Enhancing Neurodegenerative Care: Stella Sarraf from Spinogenix in an Enlightening Dialogue Exchange with PharmaShots

Shots: With a broad portfolio of candidates in ALS, Alzheimer’s disease, Schizophrenia, and Fragile X Syndrome, Spinogenix initiated the P-II study evaluating SPG302 for the treatment of patients with Alzheimer’s disease SPG302, a synaptic regenerative therapy, is aimed to provide an effective and patient-friendly solution as a daily pill for ALS and Alzheimer’s disease Today…

BySaurabh ChaubeyOctober 14, 2024

PharmaShots Interview: Tetra Therapeutics’ Mark Gurney Shares Insight on Topline Results of BPN14770 for Fragile X Syndrome

In an interview with PharmaShots, Mark Gurney, CEO at Tetra Therapeutics shared his views on the results of the P-II exploratory study of BPN14770 in adult patients with Fragile X Syndrome. Shots: The P-II study is a two-way crossover study assessing BPN14770 (25mg, bid) vs PBO in 30 adult male patients aged 18-45yrs. with FXS due to >200 CGG…

BySenior EditorMarch 1, 2021

Servier to Acquire KER-0193 from Kaerus Bioscience for ~$450M

Enhancing Neurodegenerative Care: Stella Sarraf from Spinogenix in an Enlightening Dialogue Exchange with PharmaShots

PharmaShots Interview: Tetra Therapeutics’ Mark Gurney Shares Insight on Topline Results of BPN14770 for Fragile X Syndrome

Contact US

OUR INFORMATION

FOLLOW US